Inhibition studies of DNA methyltransferases by maleimide derivatives of RG108 as non-nucleoside inhibitors.

AIM DNA methyltransferases (DNMTs) are important drug targets for epigenetic therapy of cancer. Nowadays, non-nucleoside DNMT inhibitors are in development to address high toxicity of nucleoside analogs. However, these compounds still have low activity in cancer cells and mode of action of these compounds remains unclear. MATERIALS & METHODS In this work, we studied maleimide derivatives of RG108 by biochemical, structural and computational approaches to highlight their inhibition mechanism on DNMTs. RESULTS Findings demonstrated a correlation between cytotoxicity on mesothelioma cells of these compounds and their inhibitory potency against DNMTs. Noncovalent and covalent docking studies, supported by crystallographic (apo structure of M.HhaI) and differential scanning fluorimetry assays, provided detailed insights into their mode of action and revealed essential residues for the stabilization of such compounds inside DNMTs. [Formula: see text].

[1]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[2]  F. Sautel,et al.  Design, Synthesis and Biological Evaluation of 4-Amino-N-(4-aminophenyl)benzamide Analogues of Quinoline-Based SGI-1027 as Inhibitors of DNA Methylation , 2014, ChemMedChem.

[3]  J. Wouters,et al.  Synthesis and Crystallographic Characterization of a Maleimide Derivative of Tryptamine , 2016 .

[4]  P. Arimondo,et al.  Design and synthesis of new non nucleoside inhibitors of DNMT3A. , 2015, Bioorganic & medicinal chemistry.

[5]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[6]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[7]  R. Roberts,et al.  Hhal methyltransferase flips its target base out of the DNA helix , 1994, Cell.

[8]  Hualiang Jiang,et al.  Identifying novel selective non-nucleoside DNA methyltransferase 1 inhibitors through docking-based virtual screening. , 2014, Journal of medicinal chemistry.

[9]  F. Lyko,et al.  Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine , 2008, International journal of cancer.

[10]  Peter A. Jones,et al.  Cellular differentiation, cytidine analogs and DNA methylation , 1980, Cell.

[11]  Ettore Novellino,et al.  Selective Non-nucleoside Inhibitors of Human DNA Methyltransferases Active in Cancer Including in Cancer Stem Cells , 2014, Journal of medicinal chemistry.

[12]  D. Hornby,et al.  Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. , 2002, Journal of Molecular Biology.

[13]  A. Jeltsch,et al.  Synthesis and evaluation of analogues of N-phthaloyl-l-tryptophan (RG108) as inhibitors of DNA methyltransferase 1. , 2014, Journal of medicinal chemistry.

[14]  Nir London,et al.  Covalent Docking of Large Libraries for the Discovery of Chemical Probes , 2014, Nature chemical biology.

[15]  M. Esteller.  Epigenetics in cancer. , 2008, The New England journal of medicine.

[16]  Peter A. Jones.  Functions of DNA methylation: islands, start sites, gene bodies and beyond , 2012, Nature Reviews Genetics.

[17]  J. Wouters,et al.  Structural basis for recognition of histone H3K36me3 nucleosome by human de novo DNA methyltransferases 3A and 3B. , 2016, Journal of structural biology.

[18]  I. Merfort.  Perspectives on sesquiterpene lactones in inflammation and cancer. , 2011, Current drug targets.

[19]  P. Pelicci,et al.  Decitabine, differently from DNMT1 silencing, exerts its antiproliferative activity through p21 upregulation in malignant pleural mesothelioma (MPM) cells. , 2009, Lung cancer.

[20]  T. Halgren.  Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94 , 1996, J. Comput. Chem..

[21]  Ivet Bahar,et al.  Coupling between Catalytic Loop Motions and Enzyme Global Dynamics , 2012, PLoS Comput. Biol..

[22]  F. Niesen,et al.  The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability , 2007, Nature Protocols.

[23]  R. Roberts,et al.  Structures of HhaI methyltransferase complexed with substrates containing mismatches at the target base , 1998, Nature Structural Biology.

[24]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[25]  José L. Medina-Franco,et al.  Homology modeling, docking and structure-based pharmacophore of inhibitors of DNA methyltransferase , 2011, J. Comput. Aided Mol. Des..

[26]  Frank Lyko,et al.  Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. , 2005, Cancer research.

[27]  S. Klimašauskas,et al.  Direct observation of cytosine flipping and covalent catalysis in a DNA methyltransferase , 2011, Nucleic acids research.

[28]  D. Patel,et al.  Structure-Based Mechanistic Insights into DNMT1-Mediated Maintenance DNA Methylation , 2012, Science.

[29]  K. Caron,et al.  Synthesis and evaluation of peptidic maleimides as transglutaminase inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[30]  Byron H. Lee,et al.  Procainamide Is a Specific Inhibitor of DNA Methyltransferase 1* , 2005, Journal of Biological Chemistry.

[31]  S. Yao,et al.  Developing new chemical tools for DNA methyltransferase 1 (DNMT 1): a small-molecule activity-based probe and novel tetrazole-containing inhibitors. , 2015, Bioorganic & medicinal chemistry.

[32]  T. Bestor,et al.  Eukaryotic cytosine methyltransferases. , 2005, Annual review of biochemistry.

[33]  Richard J. Roberts,et al.  Crystal structure of the Hhal DNA methyltransferase complexed with S-adenosyl-l-methionine , 1993, Cell.

[34]  K. Ghoshal,et al.  A new class of quinoline-based DNA hypomethylating agents reactivates tumor suppressor genes by blocking DNA methyltransferase 1 activity and inducing its degradation. , 2009, Cancer research.

[35]  Thomas Stützle,et al.  Empirical Scoring Functions for Advanced Protein-Ligand Docking with PLANTS , 2009, J. Chem. Inf. Model..

[36]  J. Medina-Franco,et al.  Nanaomycin A Selectively Inhibits DNMT3B and Reactivates Silenced Tumor Suppressor Genes in Human Cancer Cells , 2010, Molecular Cancer Therapeutics.

[37]  A. Jeltsch,et al.  C5‐DNA Methyltransferase Inhibitors: From Screening to Effects on Zebrafish Embryo Development , 2011, Chembiochem : a European journal of chemical biology.

[38]  A. Razin,et al.  Cloning, characterization, and expression in Escherichia coli of the gene coding for the CpG DNA methylase from Spiroplasma sp. strain MQ1(M.SssI). , 1990, Nucleic acids research.

[39]  Juan Aranda,et al.  Unraveling the Reaction Mechanism of Enzymatic C5-Cytosine Methylation of DNA. A Combined Molecular Dynamics and QM/MM Study of Wild Type and Gln119 Variant , 2016 .

[40]  R. Roberts,et al.  Purification, crystallization, and preliminary X-ray diffraction analysis of an M.HhaI-AdoMet complex. , 1992, Biochemistry.

[41]  R. Nunes,et al.  Synthesis and biological evaluation of N-antipyrine-4-substituted amino-3-chloromaleimide derivatives. , 2010, European journal of medicinal chemistry.

[42]  M. Karplus,et al.  CHARMM: A program for macromolecular energy, minimization, and dynamics calculations , 1983 .

[43]  Frank Lyko,et al.  DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. , 2005, Journal of the National Cancer Institute.

[44]  John Calvin Reed,et al.  Inhibition of Bfl-1 with N-aryl maleimides. , 2010, Bioorganic & medicinal chemistry letters.

[45]  Guido Marcucci,et al.  Curcumin is a potent DNA hypomethylation agent. , 2009, Bioorganic & medicinal chemistry letters.

[46]  R. Roberts,et al.  Structure of a binary complex of HhaI methyltransferase with S-adenosyl-L-methionine formed in the presence of a short non-specific DNA oligonucleotide. , 1999, Journal of molecular biology.

[47]  R. Roberts,et al.  Enzymatic C5-cytosine methylation of DNA: mechanistic implications of new crystal structures for HhaL methyltransferase-DNA-AdoHcy complexes. , 1996, Journal of molecular biology.

[48]  Lucia Altucci,et al.  Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. , 2009, The international journal of biochemistry & cell biology.

[49]  R. Nunes,et al.  Antifungal Properties of Novel N- and α,β-Substituted Succinimides against Dermatophytes , 2003, Arzneimittelforschung.

[50]  D. Rao,et al.  Structure, Function, and Mechanism of HhaI DNA Methyltransferases , 2002, Critical reviews in biochemistry and molecular biology.

[51]  G. Muccioli,et al.  Synthesis and in vitro evaluation of N-substituted maleimide derivatives as selective monoglyceride lipase inhibitors. , 2009, Journal of medicinal chemistry.

[52]  P. Arimondo,et al.  Development of a universal radioactive DNA methyltransferase inhibition test for high-throughput screening and mechanistic studies , 2013, Nucleic acids research.

[53]  Guido Marcucci,et al.  Modulation of DNA Methylation by a Sesquiterpene Lactone Parthenolide , 2009, Journal of Pharmacology and Experimental Therapeutics.

[54]  J. Christman,et al.  5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy , 2002, Oncogene.

[55]  R. J. Doerksen,et al.  Probing the physicochemical and structural requirements for glycogen synthase kinase-3alpha inhibition: 2D-QSAR for 3-anilino-4-phenylmaleimides. , 2006, Bioorganic & medicinal chemistry.

[56]  Kai Zhu,et al.  Docking Covalent Inhibitors: A Parameter Free Approach To Pose Prediction and Scoring , 2014, J. Chem. Inf. Model..

[57]  T. Bestor,et al.  The DNA methyltransferases of mammals. , 2000, Human molecular genetics.

[58]  J. Christman,et al.  Mechanism of inhibition of DNA (cytosine C5)-methyltransferases by oligodeoxyribonucleotides containing 5,6-dihydro-5-azacytosine. , 1999, Journal of molecular biology.

[59]  Takayoshi Suzuki,et al.  Design, synthesis, inhibitory activity, and binding mode study of novel DNA methyltransferase 1 inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[60]  J. Briand,et al.  Methyl 2-((succinimidooxy)carbonyl)benzoate (MSB): a new, efficient reagent for N-phthaloylation of amino acid and peptide derivatives. , 2002, The Journal of organic chemistry.

[61]  Manfred J. Sippl,et al.  NQ-Flipper: validation and correction of asparagine/glutamine amide rotamers in protein crystal structures , 2006, Bioinform..

[62]  N. Reguart,et al.  Wnt inhibitory factor-1, a Wnt antagonist, is silenced by promoter hypermethylation in malignant pleural mesothelioma. , 2006, Biochemical and biophysical research communications.

[63]  Frank Lyko,et al.  Discovery of two novel, small-molecule inhibitors of DNA methylation. , 2006, Journal of medicinal chemistry.

[64]  Xiaodong Cheng,et al.  Structure of Dnmt3a bound to Dnmt3L suggests a model for de novo DNA methylation , 2007, Nature.

[65]  J. Issa,et al.  Targeting DNA Methylation , 2009, Clinical Cancer Research.

[66]  Jean-Marc Gregoire,et al.  DNA methylation inhibitors in cancer: recent and future approaches. , 2012, Biochimie.

[67]  A. Wutz.  Gene silencing in X-chromosome inactivation: advances in understanding facultative heterochromatin formation , 2011, Nature Reviews Genetics.

[68]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[69]  P. Arimondo,et al.  Targeting DNA methylation with small molecules: what's next? , 2015, Journal of medicinal chemistry.

[70]  M. Lübbert,et al.  Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML). , 2006, Leukemia research.

[71]  L. Willems,et al.  The role of epigenetics in malignant pleural mesothelioma. , 2013, Lung cancer.